225 related articles for article (PubMed ID: 28264616)
21. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
Pellegrini C; Dodero A; Chiappella A; Monaco F; Degl'Innocenti D; Salvi F; Vitolo U; Argnani L; Corradini P; Zinzani PL;
J Hematol Oncol; 2016 Apr; 9():38. PubMed ID: 27071522
[TBL] [Abstract][Full Text] [Related]
22. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study.
Maruyama D; Tobinai K; Ogura M; Uchida T; Hatake K; Taniwaki M; Ando K; Tsukasaki K; Ishida T; Kobayashi N; Ishizawa K; Tatsumi Y; Kato K; Kiguchi T; Ikezoe T; Laille E; Ro T; Tamakoshi H; Sakurai S; Ohtsu T
Int J Hematol; 2017 Nov; 106(5):655-665. PubMed ID: 28664499
[TBL] [Abstract][Full Text] [Related]
23. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data.
Bates SE; Eisch R; Ling A; Rosing D; Turner M; Pittaluga S; Prince HM; Kirschbaum MH; Allen SL; Zain J; Geskin LJ; Joske D; Popplewell L; Cowen EW; Jaffe ES; Nichols J; Kennedy S; Steinberg SM; Liewehr DJ; Showe LC; Steakley C; Wright J; Fojo T; Litman T; Piekarz RL
Br J Haematol; 2015 Jul; 170(1):96-109. PubMed ID: 25891346
[TBL] [Abstract][Full Text] [Related]
24. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.
Dupuis J; Morschhauser F; Ghesquières H; Tilly H; Casasnovas O; Thieblemont C; Ribrag V; Bossard C; Le Bras F; Bachy E; Hivert B; Nicolas-Virelizier E; Jardin F; Bastie JN; Amorim S; Lazarovici J; Martin A; Coiffier B
Lancet Haematol; 2015 Apr; 2(4):e160-5. PubMed ID: 26687958
[TBL] [Abstract][Full Text] [Related]
25. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
[TBL] [Abstract][Full Text] [Related]
26. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides.
Foss F; Duvic M; Lerner A; Waksman J; Whittaker S
Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):637-643. PubMed ID: 27637428
[TBL] [Abstract][Full Text] [Related]
27. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.
Piekarz RL; Frye R; Prince HM; Kirschbaum MH; Zain J; Allen SL; Jaffe ES; Ling A; Turner M; Peer CJ; Figg WD; Steinberg SM; Smith S; Joske D; Lewis I; Hutchins L; Craig M; Fojo AT; Wright JJ; Bates SE
Blood; 2011 Jun; 117(22):5827-34. PubMed ID: 21355097
[TBL] [Abstract][Full Text] [Related]
28. Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program.
Zinzani PL; Pellegrini C; Cerciello G; Monaco F; Volpetti S; Peli A; Angelucci E; Corradini P; Cox MC; Guarini A; Musso M; Bresciani P; Amato G; Billio A; Caparrotti G; Figuera A; Nassi L; Gaudio F; Grossi A; Onida F; Merli M; Rigacci L; Argnani L
Leuk Lymphoma; 2016 Oct; 57(10):2370-4. PubMed ID: 26732313
[TBL] [Abstract][Full Text] [Related]
29. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy.
Duvic M; Bates SE; Piekarz R; Eisch R; Kim YH; Lerner A; Robak T; Samtsov A; Becker JC; McCulloch W; Waksman J; Whittaker S
Leuk Lymphoma; 2018 Apr; 59(4):880-887. PubMed ID: 28853310
[TBL] [Abstract][Full Text] [Related]
30. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
Piekarz RL; Frye R; Turner M; Wright JJ; Allen SL; Kirschbaum MH; Zain J; Prince HM; Leonard JP; Geskin LJ; Reeder C; Joske D; Figg WD; Gardner ER; Steinberg SM; Jaffe ES; Stetler-Stevenson M; Lade S; Fojo AT; Bates SE
J Clin Oncol; 2009 Nov; 27(32):5410-7. PubMed ID: 19826128
[TBL] [Abstract][Full Text] [Related]
31. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.
Iwamoto FM; Lamborn KR; Kuhn JG; Wen PY; Yung WK; Gilbert MR; Chang SM; Lieberman FS; Prados MD; Fine HA
Neuro Oncol; 2011 May; 13(5):509-16. PubMed ID: 21377994
[TBL] [Abstract][Full Text] [Related]
32. Romidepsin: a novel histone deacetylase inhibitor for cancer.
Bertino EM; Otterson GA
Expert Opin Investig Drugs; 2011 Aug; 20(8):1151-8. PubMed ID: 21699444
[TBL] [Abstract][Full Text] [Related]
33. Romidepsin for peripheral T-cell lymphoma.
Khot A; Dickinson M; Prince HM
Expert Rev Hematol; 2013 Aug; 6(4):351-9. PubMed ID: 23991922
[TBL] [Abstract][Full Text] [Related]
34. Romidepsin for the treatment of non-Hodgkin's lymphoma.
Yazbeck VY; Grant S
Expert Opin Investig Drugs; 2015; 24(7):965-79. PubMed ID: 25936363
[TBL] [Abstract][Full Text] [Related]
35. Development of new agents for peripheral T-cell lymphoma.
Ito Y; Makita S; Tobinai K
Expert Opin Biol Ther; 2019 Mar; 19(3):197-209. PubMed ID: 30658046
[TBL] [Abstract][Full Text] [Related]
36. Nursing Roles in Cardiac Safety: Romidepsin in Patients With T-Cell Lymphoma.
Hronek J; Reed M
Oncol Nurs Forum; 2016 Mar; 43(2):227-34. PubMed ID: 26906133
[TBL] [Abstract][Full Text] [Related]
37. Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.
Noonan AM; Eisch RA; Liewehr DJ; Sissung TM; Venzon DJ; Flagg TP; Haigney MC; Steinberg SM; Figg WD; Piekarz RL; Bates SE
Clin Cancer Res; 2013 Jun; 19(11):3095-104. PubMed ID: 23589175
[TBL] [Abstract][Full Text] [Related]
38. Romidepsin-associated cardiac toxicity and ECG changes: A case report and review of the literature.
Rivers ZT; Oostra DR; Westholder JS; Vercellotti GM
J Oncol Pharm Pract; 2018 Jan; 24(1):56-62. PubMed ID: 27708192
[TBL] [Abstract][Full Text] [Related]
39. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.
Bates SE; Zhan Z; Steadman K; Obrzut T; Luchenko V; Frye R; Robey RW; Turner M; Gardner ER; Figg WD; Steinberg SM; Ling A; Fojo T; To KW; Piekarz RL
Br J Haematol; 2010 Jan; 148(2):256-67. PubMed ID: 19874311
[TBL] [Abstract][Full Text] [Related]
40. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma.
Foss F; Coiffier B; Horwitz S; Pro B; Prince HM; Sokol L; Greenwood M; Lerner A; Caballero D; Baran E; Kim E; Nichols J; Balser B; Wolfson J; Whittaker S
Biomark Res; 2014; 2():16. PubMed ID: 25279222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
